ANZCTR search results

This is a prospective randomized controlled trial (RCT) comparing patient outcomes in patients undergoing anterior cruciate ligament reconstruction (ACLR) with one of two autograft constructs: 1) a hamstring tendon (HT) autograft, or 2) a peroneus longus tendon (PLT) autograft. Patient outcomes will be collected and compared between the two surgical autograft cohorts over a 24 month post-operative period. This will include limb symmetry index of peak isokinetic knee flexor strength at 12 months (primary outcome variable), a range of patient reported outcome measures (PROMs), objective measures including anterior knee laxity, knee range of motion (ROM), quadriceps and hamstring strength, ankle eversion and plantarflexion strength, and functional performance tests including single limb hop and vertical/horizontal jump capacity. Donor site morbidity will also be assessed using specific questionnaires and patient-reported measures. It is hypothesised that patients undergoing ACL reconstruction via PLT autograft, will have earlier recovery of knee flexion strength and lower donor site morbidity compared with patients receiving a HT autograft.

This study will test whether a mobile “tap-per-breath” application helps paramedic students measure a patient’s breathing rate more accurately and quickly than the current standard method of using a watch or clock. Participants will complete two simulated patient assessments, one using the app and one using the traditional method. The study hypothesis is that the tap-per-breath application will improve the accuracy and efficiency of respiratory rate measurement, while reducing the mental effort required.

This study aims to better understand how obesity and type 2 diabetes affect the heart before symptoms or disease are clinically diagnosed. We will use advanced MRI scans and blood tests to measure heart structure, function, energy use, fat content, and blood vessel health. Participants will include healthy adults and those with obesity or type 2 diabetes. The results will help researchers identify early warning signs of heart disease and improve how we prevent or treat it in the future. All participants will attend one research visit at the Baker Heart and Diabetes Institute in Melbourne.

Depression is a highly recurrent disorder (Katon et al, 2001; Kessing et al., 2004). Research has shown that symptoms of depression are related to a difficulty retrieving personal memories and imagining future events that you might personally experience, and that these difficulties may persist in people with remitted depression (Gamble et al., 2019; Hallford, Rusanov et al., 2022; Liu et al., 2013). Therefore, targeting these cognitive processes may be advantageous for individuals with remitted MDD. To the author’s knowledge, no study to date has trialled an intervention that targets autobiographical thinking pathways in order to reduce severity of cognitive vulnerability factors associated with depressive relapse in individuals with remitted MDD. Aim: Conduct a proof-of-concept pilot trial to test an Autobiographical Thinking Training Program in people with Remitted MDD. Objectives: Examine whether this program has an effect on autobiographical thinking (memory and future thinking) by the 3 month endpoint (primary outcome); as well as secondary outcomes of depressive symptoms, anticipatory pleasure, suicidal ideation, anxiety symptoms, psychosocial functioning, self-efficacy, self-esteem, behavioural activation, perceived control, optimism and meaning in life. Hypotheses: 1. Participants in the Autobiographical Thinking Training (ATT) will report significantly increased autobiographical thinking (i.e., specificity, detail, imagery, vividness of memories and future thoughts) at post-intervention, and at the 3 month follow-up. 2. Participants will report significantly fewer depressive symptoms, suicidal ideation, and anxiety symptoms; and significantly increased anticipatory pleasure, psychosocial

The Gulibaa project is an Indigenous-led and community embedded project to co-design, implement and evaluate a model of care to support Aboriginal and Torres Strait Islander women to be smoke and vape-free. The aim of the Gulibaa project is to reduce the prevalence of smoking among Aboriginal and Torres Strait Islander women by developing and implementing group-based smoking cessation care within Aboriginal Health Services. We hypothesis that Aboriginal and Torres Strait Islander women who attend the group-based program will increase self-reported abstinence and quit attempt frequency.

The purpose of this research is to compare the new Kali Monitoring System to standard-of-care cardiotocography, and evaluate its reliability, safety and usability.

This study aims to assess if it is feasible and accurate to use a novel PET scan to identify pulmonary Graft Versus Host Disease (GVHD) following haematopoietic stem cell transplant (HSCT) for blood cancers earlier than conventional and invasive testing. Who is it for? You may be eligible for this study if you are an adult allogeneic HSCT recipient at Royal Brisbane and Women's Hospital, with an existing diagnosis of pulmonary cGVHD (bronchiolitis obliterans syndrome [BOS], cryptogenic organising pneumonia [COP], or interstitial lung disease [ILD]). Study details Participants will undergo a single 68-Ga Fibroblast Activating Protein Inhibitor (FAPI) scan, as well as other testing modalities such as spirometry, high resolution CT scan and clinical questionnaires. These modalities will be compared against each other to determine the ability of the FAPI PET scan to detect lung scarring in pulmonary GVHD. It is hoped that findings from this study will help researchers develop new and less invasive ways to detect pulmonary GVHD to facilitate earlier management and intervention.

Temporomandibular disorders (TMD) are a group of conditions that affect the jaw joint (temporomandibular joint), the surrounding musculature, and the nerves related to chronic facial pain. Unlike other TMD therapy modalities photobiomodulation (PBM) is widely regarded for its clinical safety, non-invasiveness, anti-inflammatory and analgesic properties. PBM has been shown to be a beneficial adjuvant when used with other TMD therapies. While photobiomodulation has been reported in several studies to effectively relieve symptoms of TMD, the mechanism of action of photobiomodulation on the early inflammatory biomarkers remains unclear. Furthermore, little is known regarding the impact of how different wavelengths of near infared lasers impact the inflammatory biomarkers in the treatment of TMD. The purpose of this study is to shed light on the dynamics of photobiomodulation via the use of Infared lasers in influencing early inflammatory cytokines, such as TNF-A and IL-1B, in TMD therapy using only patient saliva samples. It is hypothesized that patients with TMD will have reduced levels of inflammatory markers following PBM treatment. This research will be conducted at the School of Dentistry and Oral Health, Griffith University, Gold Coast and at The Thirty Two- a private dental practice located at T28/129 Queen St, Gold Coast.

The primary purpose of this study is to evaluate the clinical efficacy and safety of topical lidocaine spray in reducing neuropathic pain is superiority in patients with Postherpetic Neuralglia (PHN) compared with those on a placebo spray.

Road-traffic injuries are often psychologically distressing; beyond the physical trauma, navigating compensation can heighten feelings of being overwhelmed and lower self-efficacy, which are linked to slower recovery and greater healthcare use. Early, clear information and supportive contact may mitigate distress and improve functional outcomes. Scalable mHealth approaches (e.g., automated SMS) offer a low-cost way to deliver timely reassurance and self-management prompts. This double-blind, two-arm randomised controlled trial (n=254) will test an SMS support program for Allianz NSW CTP claimants. All participants receive usual customer support plus two short videos delivered via SMS links (claims navigation and pain self-management). The intervention arm also receives once-daily supportive SMS for 28 days; the control arm receives the videos only (no SMS). The primary outcome is pain self-efficacy; secondary outcomes include claims satisfaction, pain, psychological distress, return to work, healthcare costs, and feasibility (adoption, engagement/reach, acceptability), assessed post-intervention and at 4 months. We anticipate that participants who receive the SMS text-messages in addition to the videos will feel more confident to manage both their claim and their pain during recovery.